Electrocore LLC (ECOR)

NASDAQ
Currency in USD
8.0300
+0.0200(+0.25%)
Closed
After Hours
8.03000.0000(0.00%)
ECOR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
7.96008.5000
52 wk Range
5.320019.4900
Key Statistics
Edit
Prev. Close
8.01
Open
7.96
Day's Range
7.96-8.5
52 wk Range
5.32-19.49
Volume
108.28K
Average Volume (3m)
145.87K
1-Year Change
26.06%
Book Value / Share
1.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ECOR Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
25.2000
Upside
+213.82%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Electrocore Company Profile

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Electrocore LLC Earnings Call Summary for Q4/2024

  • ElectroCore's revenue grew 57% YoY to $25.2M in 2024, with gross margin improving to 85%, but stock fell 3.85% in aftermarket trading
  • Net loss reduced 37% to $11.9M; cash and equivalents increased to $12.2M; cash used in operations decreased 53% to $7M
  • Company launched Truvega wellness product line and acquired NeuroMetrix, expanding presence in U.S. chronic pain and wellness markets
  • No specific 2025 guidance due to pending NeuroMetrix acquisition; analysts target $20-$29 per share, suggesting potential upside
  • CEO confident in growth trajectory, citing leadership in non-invasive nerve stimulation and focus on expanding wellness market
Last Updated: 13-03-2025, 04:20 am
Read Full Transcript

Compare ECOR to Peers and Sector

Metrics to compare
ECOR
Peers
Sector
Relationship
P/E Ratio
−4.9x−2.0x−0.5x
PEG Ratio
−0.09−0.130.00
Price/Book
7.7x1.2x2.6x
Price / LTM Sales
2.3x5.0x3.0x
Upside (Analyst Target)
211.3%42.6%54.1%
Fair Value Upside
Unlock6.6%9.4%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 25.2000
(+213.82% Upside)

Earnings

Latest Release
May 03, 2023
EPS / Forecast
-1.24 / -1.00
Revenue / Forecast
2.78M / 2.95M
EPS Revisions
Last 90 days

FAQ

What Is the Electrocore (ECOR) Stock Price Today?

The Electrocore stock price today is 8.03.

What Stock Exchange Does Electrocore Trade On?

Electrocore is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Electrocore?

The stock symbol for Electrocore is "ECOR."

What Is the Electrocore Market Cap?

As of today, Electrocore market cap is 58.12M.

What is Electrocore Earnings Per Share?

The Electrocore EPS is -1.59.

From a Technical Analysis Perspective, Is ECOR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.